Clinical trial NCT04378647: BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Official title: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy With Brentuximab Vedotin-ESHAP vs ESHAP in Patients With Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (Instead of Autologous Hematopoietic Stem Cell Transplantation) in Those Who Attained a Metabolic Complete Remission After Salvage Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Hodgkin Lymphoma, Adult
Lead sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Sponsor class: OTHER
First posted: 2020-05-07
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

Detailed description: A phase IIb open label multi-center trial in patients with refractory / relapsed cHL.

Patients are randomized (1:1) to receive:

• ESHAP- BV (Etoposide \[40 mg/m2/ day IV, D1-4\], Solumedrol \[250 mg/day IV, D1-4\], high dose Ara-C \[2 g/m2 IV, D5\] and cisplatinum \[25 mg/m2/day IV, D1-4\] + BV \[1.8 mg/kg IV, D1\], every 21 days (3 cycles, q21 days).

Or

• ESHAP (Etoposide \[40 mg/m2/ day IV, D1-4\], Solumedrol \[250 mg/day IV, D1-4\], high dose Ara-C \[2 g/m2 IV, D5\] and cisplatinum \[25 mg/m2/day IV, D1-4\] (3 cycles, q21 days)

Stem cell collection will be performed in all patients according to institutional guidelines, but preferably after the first / second cycle of ESHAP-BV or ESHAP.

Patients attaining a mCR (Deauville 1, 2) after receiving 3 cycles of ESHAP-BV, will receive up to 13 cycles of BV consolidation (administered every 3 weeks, over 39 weeks).

Patients who were randomized to ESHAP and attained a mCR after receiving 3 cycles will receive up to 16 cycles of BV (same dosage and time intervals).

Patients who attained less than mCR following ESHAP-BV/ESHAP they will be taken out of the trial and will be treated according to their physician's clinical decision. However, they will be followed in order to evaluate their clinical outcome in terms of ORR, CR rate, TTNT2 and OS, that will be analyzed the study separately.

Eligibility criteria: Inclusion Criteria:

Patients with classical HL CD30+ confirmed histologically (either at the time of diagnosis / at the time of first relapse) will be included in the trial

* Male or female patients 18 to 65 years of age
* Voluntary written informed consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
* Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
* Male patients, even if surgically sterilized, (i.e., status post-vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
* ECOG 0 to 2
* Measurable disease at time of enrolment (lymphadenopathy/ extranodal mass of at least 1.5 cm)
* No evidence of neuropathy grade ≥2
* Clinical laboratory values as specified in the protocol below within 7 days before the first dose of study drug

Exclusion Criteria:

* Lymphocyte predominant nodular Hodgkin's lymphoma
* Prior treatment with brentuximab vedotin
* Female patient who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug
* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.
* Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
* Symptomatic neurologic disease compromising normal activities of daily living or requiring medic
* Any sensory or motor peripheral neuropathy greater than or equal to Grade 2
* Known history of any of the following cardiovascular conditions defined in the protocol
* Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
* Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives (or 28 days if the half-lives are unknown) of last dose of that prior treatment
* Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
* Known human immunodeficiency virus (HIV) positive
* Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
* Focal radiation therapy within 30 days prior to study recruitment
* Major surgery within 28 days prior to randomization
* Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
* Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Primary outcomes:
measure: PET-CT result
timeFrame: 4-6 weeks after the Cycle 3 started (each cycle is 21 days)
Secondary outcomes:
measure: progression-free survival (PFS)
timeFrame: At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
measure: Duration of response
timeFrame: At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
measure: Overall Survival (OS)
timeFrame: At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
measure: Duration of response (DOR)
timeFrame: At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
Other outcomes:
measure: Safety and tolerability
timeFrame: At the end of the 3 years of of last dose of consoldation Brentuximab VEdotin treatment
Locations:
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias
state: Asturias
city: Barcelona
country: Spain
facility: Institut Català D'Oncologia - Hospital Germans Trias I Pujol
state: Barceolna
city: Santander
country: Spain
facility: Hospital Universitario Marqués de Valdecilla
state: Cantabria
city: A Coruña
country: Spain
facility: Complexo Hospitalario Universitario A Coruña
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
city: BArcelona
country: Spain
facility: Hospital de La Santa Creu I Sant Pau
city: Barcelona
country: Spain
facility: Institut Català D'Oncologia - Hospital Duran I Reynals
city: Barcelona
country: Spain
facility: Institut Català D'Oncologia
city: Bilbao
country: Spain
facility: Hospital Universitario de Cruces
city: Granada
country: Spain
facility: Hospital Universitario Virgen de Las Nieves
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañón
city: Madrid
country: Spain
facility: Hospital Ramón Y Cajal
city: Madrid
country: Spain
facility: Hospital Universitario Fundación Jiménez Díaz
city: MAdrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Murcia
country: Spain
facility: Hospital General Universitario J.M. Morales Meseguer
city: Salamanca
country: Spain
facility: Hospital Universitario de Salamanca
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Del Rocío
city: Valencia
country: Spain
facility: Hospital Universitario Y Politécnico La Fe
city: Valencia
country: Spain
facility: Hospital Clínico Universitario de Valencia
Study officials:
affiliation: Institut Català d'Oncologia, Hospital Duran i Reynals
name: Anna Sureda, PhD
role: PRINCIPAL_INVESTIGATOR
References: